{"url_path":"/sec/ltrn/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-023200-index.html","accession_number":"0001493152-26-023200","cik":"0001763950","ticker":"LTRN","issuer_name":"Lantern Pharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-023200-index.html","primary_entity_key":"0001763950","primary_entity_name":"Lantern Pharma Inc."},"word_count":145,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits**\n\n \n\n**(d)\nExhibits**\n\n \n\nThe\nfollowing exhibits are filed with this report:\n\n \n\n**Exhibit\nNumber**\n \n**Exhibit\nDescription**\n\n4.1\n \n[Form of Pre-Funded Common Stock Purchase Warrant](ex4-1.htm)\n\n4.2\n \n[Form of Purchase Warrant](ex4-2.htm)\n\n4.3\n \n[Form of Placement Agent Warrant](ex4-3.htm)\n\n5.1\n \n[Legal Opinion of Greenberg Traurig, LLP](ex5-1.htm)\n\n10.1\n \n[Securities Purchase Agreement](ex10-1.htm)\n\n23.1\n \n[Consent of Greenberg Traurig, LLP (included in Exhibit 5.1)](ex5-1.htm)\n\n99.1\n \n[Press release dated May 13, 2026 announcing the pricing of the Offering](ex99-1.htm)\n\n99.2\n \n[Press release dated May 14, 2026 announcing the closing of the Offering](ex99-2.htm)\n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n** **\n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**Lantern Pharma Inc.**\n\n \n \n \n\nDated:\nMay 14, 2026\nBy:\n*/s/\nDavid Margrave*\n\n \n \nDavid\nMargrave\n\n \n \nChief\nFinancial Officer\n\n** **\n\n \n\n** **"}